Pacific Biosciences (PACB) Fundamental Analysis: Revenue, Earnings & Valuation

0.32 / 10

Underperform

Fundamental rating is Underperform with a 0.3/10 score. Revenue‑MV and Cash‑UP show modest strengths, while Profit‑MV, Net income‑Revenue and profit margins are poor. Overall, the company lacks solid earnings and balance‑sheet health, limiting its investment appeal.

Analysis Checks(2/10)

Revenue-MV

Value-0.67

Score3/3

Weight-145.85%

1M Return3.85%

Net cash flow from operating activities / Operating revenue (%)

Value-69.50

Score1/3

Weight8.42%

1M Return-0.28%

Profit-MV

Value0.66

Score1/3

Weight87.72%

1M Return-2.85%

Net income-Revenue

Value-0.04

Score1/3

Weight78.52%

1M Return-2.58%

Net profit margin (%)

Value-341.47

Score1/3

Weight-7.12%

1M Return0.24%

Cash-UP

Value-0.15

Score3/3

Weight-92.18%

1M Return2.45%

Net cash flow from operating activities / Total liabilities (%)

Value-0.14

Score1/3

Weight115.32%

1M Return-4.08%

EBIT / Total operating revenue (%)

Value-336.93

Score1/3

Weight17.12%

1M Return-0.58%

Asset-MV

Value-0.55

Score1/3

Weight45.18%

1M Return-2.84%

Net profit / Total operating revenue (%)

Value-341.47

Score1/3

Weight-7.12%

1M Return0.24%

Is PACB undervalued or overvalued?

PACB scores 0.32/10 on fundamentals and holds a Premium valuation at present. Backed by its -213.45% ROE, -341.47% net margin, -0.70 P/E ratio, 71.14 P/B ratio, and -61.06% earnings growth, these metrics solidify its Underperform investment rating.